Coherus BioSciences (CHRS) Scheduled to Post Earnings on Thursday

Coherus BioSciences (NASDAQ:CHRS) is set to issue its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The firm had revenue of $77.06 million for the quarter, compared to analyst estimates of $102.00 million. During the same quarter last year, the firm posted ($0.89) EPS. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus BioSciences Trading Up 1.9 %

NASDAQ:CHRS traded up $0.03 during trading hours on Tuesday, hitting $1.35. 956,456 shares of the company traded hands, compared to its average volume of 2,752,781. Coherus BioSciences has a twelve month low of $1.24 and a twelve month high of $5.47. The firm has a 50-day moving average of $1.64 and a 200 day moving average of $2.07. The stock has a market capitalization of $154.31 million, a price-to-earnings ratio of -1.69 and a beta of 0.60.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CHRS. StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Friday, July 26th. Truist Financial cut their price target on Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating for the company in a report on Monday, May 13th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Coherus BioSciences in a report on Monday. Finally, Robert W. Baird lowered their price objective on Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Monday, July 1st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Coherus BioSciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.